Building a Digital Health Startup with Shuo Qiao of Moving Analytics
Listen now
Description
Today on the show we're joined by Shuo Qiao, Co-founder and Chief Technology Officer of Moving Analytics. We discuss his career path and how it earned him a spot on the Forbes 30 Under 30 list, his interest in computer science, and crossing paths with his future business partner. Dive into funding strategies, the rise and global impact of telehealth, and the future of digital health tech on this episode of From Lab to Launch. About Shuo Qiao Shuo Qiao is the Co-founder and Chief Technology Officer of Moving Analytics. Shuo earned his bachelor's degree in computer science degree from Beijing Jiaotong University and the top engineering university in India, the Indian Institute of Technology Madras. In 2013, he moved to the US to pursue his master's degree in computer science from the University of Southern California. He’s now the Co-founder and Chief Technology Officer of Moving Analytics, a digital health company that reduces the chance of a heart attack through digital cardiovascular disease prevention programs. About Moving Analytics Moving Analytics is a digital health company with the mission to conquer cardiovascular disease as the leading cause of death by empowering people with tools to adopt healthy lifestyles. They work with a multidisciplinary team of cardiologists, nurses, nutritionists, and exercise physiologists to create personalized rehab programs for heart attack patients which they can access anywhere through their mobile phones. Links Shuo Qiao | LinkedIn: https://www.linkedin.com/in/shuo-qiao-0b813452/ Moving Analytics: https://www.movinganalytics.com/ Forbes 30 Under 30: https://www.forbes.com/30-under-30/2018/healthcare/ Qualio website: https://www.qualio.com/ Previous episodes: https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show: https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez 
More Episodes
Listen in on our conversation with Rob Etherington, CEO of Clene Nanomedicine, a company pioneering nanotherapeutics for neurodegenerative diseases like ALS, multiple sclerosis, and Parkinson's. Rob discusses Clene's unique approach to improve mitochondrial function through a novel...
Published 04/24/24
Published 04/24/24